ASX:
Nature Biopharma
New class of synthetic antibiotics set to tackle superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
read full article
Fighting Antibiotic Resistance
The world needs new classes of antibiotics Antibiotics
The world needs new classes of antibiotics Antibiotics are used as our frontline treatment...
BioWorld
Recce nears clinic with ‘master key’ antibiotic to take on superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
read full article
The Australian
Australia’s Recce strives for immune-proof super-antibiotic Introductory offers to be billed as follows: The Australian Digital Subscription costs 50c per day, billed monthly (min cost up...
read full article
The West Australian
WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started ...
read full article
S&P Global
Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery...
read full article
Sky Business News
Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..
read full article
Health & Biotech
Why this 29-year-old investor took a six-figure stake in a $17m biotech company I prefer to have my money be working for me,” he tells Stockhead. “I don’t want it to be at the beck and call of Trump having...
read full article
